ERBB2 and cancer: Results revealed that lapatinib in combination with brusatol exhibited a significantly enhanced inhibitory activity than that of either agent alone in all three HER2-positive cancer cells including SK-BR-3, SK-OV-3 and AU565 cancer cells (Figure 1A).